The global chronic kidney disease drugs market, by Drug Class (ACE Inhibitors, B- Blockers, Calcium Channel Blockers, Diuretics, Erythropoiesis-Stimulating Agents (ESAs), and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 12,468.2 million in 2017 and is projected to exhibit a CAGR of 3.1% over the forecast period (2018 – 2026).
Availability of wide number of drugs for diseases such as diabetes (generic as well as branded), disease awareness initiatives, and ongoing research and development of different therapies are expected to fuel growth of the chronic kidney disease drugs market over the forecast period. In 2017, Amgen, Inc. received the U.S. Food & Drug Administration (FDA) approval for Parsabiv (Etelcalcetide), which can be used for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease. Cipla launched generic version of Genzyme Corporation’s Renvela tablets in the U.S. in 2017. Moreover, Aurobindo pharma also launched generic Renvela in 2017 in the U.S. to control serum phosphorus in chronic kidney disease patients. In January 2018, Mitsubishi Tanabe Pharma Corporation launched Kremezin tablets for chronic renal failure. OPKO Health, Inc. launched Rayaldee (calcifediol) capsules in the U.S. in 2016. Dr. Reddy’s Laboratories launched generic version of Paricalcitol injection for the treatment of chronic kidney disease in 2016. Browse 29 Market Data Tables and 47 Figures spread through 178 Pages and in-depth TOC on Chronic Kidney Disease Drugs Market, by Drug Class (ACE Inhibitors, B- Blockers, Calcium Channel Blockers, Diuretics, Erythropoiesis-Stimulating Agents (ESAs), and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026
To know the latest trends and insights prevalent in the chronic kidney disease drugs market, click the link below:
Ongoing research and development for chronic kidney disease medications is expected to boost the market growth over the forecast period. For instance, in January 2018, Cara Therapeutics initiated pivotal phase III trial of Korsuva (CR845/difelikefalin) injection for hemodialysis patients with chronic kidney disease-associated pruritus. DaVita Clinical Research (DVR), a health care provider-based specialty research organization launched Alliance Site Network for early stage chronic kidney disease trials in 2017. This network will provide a clinical research infrastructure to nephrology researchers in the U.S. Moreover, AstraZeneca Plc. announced two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure in 2016. In March 2018, the U.S. Department of Health and Human Services (HHS) collaborated with American Society of Nephrology to launch Kidney Innovation Accelerator (KidneyX) to accelerate innovation in kidney disease diagnosis and treatment.
Key Takeaways of the Chronic Kidney Disease Drugs Market: